Skip to content
OrphoMed logo — Innovative solutions for visceral hypersensitivity and pancr...

OrphoMed

Innovative solutions for visceral hypersensitivity and pancreatitis through pioneering therapeutic dimer conjugates.

Founded 2015 Series A Total: $41.82M Biotechnology, Pharmaceutical

General Information

Company Name OrphoMed
Founded Year 2015
Founders / Decision Makers
Team member
Industries Biotechnology, Pharmaceutical
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with OrphoMed. To contact OrphoMed, visit orphomed.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does OrphoMed compare?

A PDF of OrphoMed and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting OrphoMed soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About OrphoMed

OrphoMed is a San Francisco Bay Area based biotechnology and pharmaceutical company established in 2015. The company focuses on developing innovative therapeutic dimer conjugates through its proprietary DIMERx™ platform technology, with the aim of addressing visceral hypersensitivity and pancreatitis in gastrointestinal disorder treatments. The leading candidate, ORP-101, is a promising peripherally acting sodium ion channel blocker and mu agonist/kappa antagonist dimer, poised for specific indications in chronic treatment of conditions associated with visceral and somatic hypersensitivity and hyperalgesia. OrphoMed also aims to develop effective non-opioid and opioid conjugates for treating acute and chronic nociceptive pain. Moreover, the company's DIMERx™ technology creates conjugates tailored for various clinical indications, with new molecular entities enjoying composition of matter intellectual property protection. OrphoMed's activities have attracted significant attention from investors, with the most recent Series A investment amounting to $39.00M and involving prominent stakeholders such as New Enterprise Associates, Pappas Capital, Takeda Pharma, Mario Family Funds, and Relativity Healthcare Partners on 24 May 2017. The company's dedication to pioneering therapeutic solutions in the biotechnology and pharmaceutical industries presents promising prospects for future growth and development.

Business keywords: pharmaceutical company, therapeutic dimer conjugates, DIMMERx technology, visceral hypersensitivity, pancreatitis, gastrointestinal disorders, peripheral neuropathic pain, systemic nociceptive pain, ORP-101, opioid alternatives, non-opioid analgesic, molecular entities, intellectual property, San Francisco Bay Area, drug development

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $39.00M 5
New Enterprise Associates, Pappas Capital +3
24 May 2017
Debt Financing $2.82M -
15 Jan 2016

OrphoMed Alternatives & Competitors

OrphoMed vs
Akelos Inc
Akelos Inc United States

Developing Opioid Alternatives for Treating Neuropathic Pain. Now Recruiting Accredited Investors -...

Grant
5 employees
Biopharma, Biotechnology
OrphoMed vs

Developing Restorative Treatments for Chronic Neuropathic Pain and Hearing Loss

Series A
15 employees
Biotechnology, Health Care

FAQ About OrphoMed

Innovative solutions for visceral hypersensitivity and pancreatitis through pioneering therapeutic dimer conjugates.
OrphoMed was founded in 2015.
OrphoMed operates in Biotechnology and Pharmaceutical. Its work centres on pharmaceutical company, therapeutic dimer conjugates, DIMMERx technology and visceral hypersensitivity.
OrphoMed has completed 2 funding rounds, raising a total of $41.82M. The latest funding stage is Series A.
Top alternatives and competitors to OrphoMed include Akelos Inc, Hoba Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
OrphoMed and Akelos Inc are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for OrphoMed, https://www.bouncewatch.com/company/orphomed, updated 27 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout